Beyond Air Inc (XAIR) - Net Assets
Based on the latest financial reports, Beyond Air Inc (XAIR) has net assets worth $6.21 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($35.38 Million) and total liabilities ($29.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Beyond Air Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.21 Million |
| % of Total Assets | 17.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | -92.06% |
| 10-Year Change | N/A |
| Growth Volatility | 136.14 |
Beyond Air Inc - Net Assets Trend (2014–2026)
This chart illustrates how Beyond Air Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Beyond Air Inc.
Annual Net Assets for Beyond Air Inc (2014–2026)
The table below shows the annual net assets of Beyond Air Inc from 2014 to 2026. Also explore XAIR year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | $6.21 Million | -56.70% |
| 2025-03-31 | $14.34 Million | -47.25% |
| 2024-03-31 | $27.19 Million | -35.31% |
| 2023-03-31 | $42.03 Million | -46.26% |
| 2022-03-31 | $78.21 Million | +156.73% |
| 2021-03-31 | $30.46 Million | +68.37% |
| 2020-03-31 | $18.09 Million | +349.52% |
| 2019-03-31 | $4.02 Million | +160.64% |
| 2018-03-31 | $1.54 Million | +6237.52% |
| 2017-03-31 | $-25.16K | 0.00% |
| 2016-03-31 | $-25.16K | +97.67% |
| 2015-03-31 | $-1.08 Million | -365.52% |
| 2014-03-31 | $-232.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beyond Air Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31782200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.02% |
| Other Comprehensive Income | $134.00K | 2.19% |
| Other Components | $325.56 Million | 5314.43% |
| Total Equity | $6.13 Million | 100.00% |
Beyond Air Inc Competitors by Market Cap
The table below lists competitors of Beyond Air Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Webac Holding AG
F:RKB
|
$2.22 Million |
|
Falcon Oil & Gas Ltd.
LSE:FOG
|
$2.23 Million |
|
ORIGEN RESOURCES INC. NEW
F:4VXA
|
$2.23 Million |
|
Avira Resources Ltd
AU:AVW
|
$2.23 Million |
|
Green Minerals AS
OL:GEM
|
$2.21 Million |
|
Uscom Ltd
AU:UCM
|
$2.21 Million |
|
Sri Havisha Hospitality and Infrastructure Limited
NSE:HAVISHA
|
$2.21 Million |
|
Majedie Investments
LSE:MAJE
|
$2.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beyond Air Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 13,583,000 to 6,126,000, a change of -7,457,000 (-54.9%).
- Net loss of 33,249,000 reduced equity.
- New share issuances of 13,335,000 increased equity.
- Other comprehensive income increased equity by 194,000.
- Other factors increased equity by 12,263,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.25 Million | -542.75% |
| Share Issuances | $13.34 Million | +217.68% |
| Other Comprehensive Income | $194.00K | +3.17% |
| Other Changes | $12.26 Million | +200.18% |
| Total Change | $- | -54.90% |
Book Value vs Market Value Analysis
This analysis compares Beyond Air Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.21x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-03-31 | $-1.60 | $3.08 | x |
| 2015-03-31 | $-7.46 | $3.08 | x |
| 2016-03-31 | $-0.02 | $3.08 | x |
| 2017-03-31 | $-0.24 | $3.08 | x |
| 2018-03-31 | $102.91 | $3.08 | x |
| 2019-03-31 | $189.44 | $3.08 | x |
| 2020-03-31 | $628.96 | $3.08 | x |
| 2021-03-31 | $676.76 | $3.08 | x |
| 2022-03-31 | $3.05 | $3.08 | x |
| 2023-03-31 | $1.40 | $3.08 | x |
| 2024-03-31 | $302.15 | $3.08 | x |
| 2025-03-31 | $80.25 | $3.08 | x |
| 2026-03-31 | $14.76 | $3.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beyond Air Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -542.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -432.99%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 5.78x
- Recent ROE (-542.75%) is below the historical average (-217.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.62 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.70 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.66 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-27.23K |
| 2018 | -1168.50% | 0.00% | 0.00x | 6.06x | $-18.20 Million |
| 2019 | -162.95% | -84.91% | 0.82x | 2.34x | $-6.96 Million |
| 2020 | -110.23% | -1434.61% | 0.05x | 1.52x | $-21.75 Million |
| 2021 | -75.09% | -2620.27% | 0.02x | 1.33x | $-25.92 Million |
| 2022 | -55.21% | -29738.27% | 0.00x | 1.27x | $-51.00 Million |
| 2023 | -132.81% | -94603.39% | 0.00x | 1.64x | $-60.02 Million |
| 2024 | -240.51% | -5197.76% | 0.02x | 2.27x | $-62.75 Million |
| 2025 | -343.26% | -1258.43% | 0.12x | 2.21x | $-47.98 Million |
| 2026 | -542.75% | -432.99% | 0.22x | 5.78x | $-33.86 Million |
Industry Comparison
This section compares Beyond Air Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $506,247,030
- Average return on equity (ROE) among peers: -29.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beyond Air Inc (XAIR) | $6.21 Million | 0.00% | 4.70x | $2.22 Million |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $177.99 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-132.02 Million | 0.00% | 0.00x | $11.08 Million |
| Aethlon Medical Inc (AEMD) | $4.89 Million | -146.36% | 0.30x | $1.02 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $245.55 Million | 0.85% | 0.03x | $800.36 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $4.97 Million |
| Allurion Technologies, Inc. (ALUR) | $-34.28 Million | 0.00% | 0.00x | $1.16 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.00 Million |
| Artivion Inc (AORT) | $7.30 Million | 9.59% | 0.70x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $9.29 Million | -10.75% | 0.15x | $126.79 Million |
About Beyond Air Inc
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and b… Read more